Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.

Antimicrobial agents and chemotherapy - 1 Jul 1990

Kaatz G W, Seo S M

Abstract excerpt

WIN 57273 is a new fluoroquinolone with excellent in vitro activity versus gram-positive pathogens, including methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis and gentamicin-susceptible and -resistant Enterococcus faecalis. We compared the microdilution MICs and MBCs of this compound to those of other antimicrobial agents for more than 30 clinical isolates of each of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to beta-Lactamases
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fluoroquinolones

Share to Microbial Sensitivity Tests

Share to Mutation

Share to Quinolones

Share to Staphylococcus aureus

Source

Open in PubMed Open full text

Identifiers

PMID: 2117417
DOI: 10.1128/AAC.34.7.1376
PMCID: PMC175984

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.PMID 2117417Read ↗

In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.Semantic proximity Read ↗

Comparative in-vitro activity of new quinolones against clinical isolates and resistant mutants.Semantic proximity Read ↗

In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.Semantic proximity Read ↗

The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.Semantic proximity Read ↗

In vitro development of resistance to a novel fluoroquinolone, DW286, in methicillin-resistant Staphylococcus aureus clinical isolates.Semantic proximity Read ↗

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agentsSemantic proximity Read ↗

In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.Semantic proximity Read ↗

In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.Semantic proximity Read ↗

In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.Semantic proximity Read ↗

Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Semantic proximity Read ↗

In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.Semantic proximity Read ↗

Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.